FOLH1 and prostate cancer: Though work has been done with these chimeras (Eli, 2010; Zhou et al., 2011), yet most prevalent one targeted for therapy is against PSMA, a cell-surface receptor over-expressed in prostate cancer cells and tumor vascular endothelium (McNamara et al., 2006).